Liver Fluke Treatment Market

Liver Fluke Treatment Market

The global liver fluke treatment market is estimated to register growth at a healthy CAGR of around 4% to 5% during the forecast period 2022-2032. Increasing research and development activities aimed at developing more effective therapeutic drugs for the treatment of liver-related diseases are projected to create growth prospects in the liver fluke treatment market over the forthcoming years.

Report Attribute	Details
Liver Fluke Treatment Market Projected Growth Rate (2022-2032)	4% to 5% CAGR

Liver fluke is a collective name of a polyphyletic parasitic trematodes group that infect humans as well as animals and cause ailment related to the liver and bile duct. These parasitic worms are commonly categorized into 2 types of infection-causing worms and termed as Fasciola Gigantica and Fasciola Hepatica, which is also known as sheep liver fluke.

Fascioliasis is an infectious disease caused by these parasites that results in severe abdominal pain, fever, hives, malaise, diarrhea, and others. Many times liver fluke infections go undiagnosed or misdiagnosed with general abdominal pain. However, growing awareness regarding the severity of the disease and the introduction of novel treatments is favoring the growth in the market.

Which are Key Drivers Augmenting the Sales of Liver Fluke Treatment in the Global Market

Over the last decade, the prevalence of infectious diseases such as liver fluke is growing at a rapid pace. This is due to the declining global immunity and rising consumption of salads comprising water-based leaves such as watercress, resulting in fueling the demand for associated diagnostics and treatment solutions.

For instance, according to the survey by the American Journal of Tropical Medicine and Hygiene, nearly 2.6 million people are estimated to be affected by fascioliasis and around 91 million people are at the risk of developing the infection across the world. As liver fluke therapeutics drugs such as praziquantel, triclabendazole, bithionol, albendazole, and nitazoxanide among others play a vital rise in the treatment of fascioliasis, rising burden of these infectious diseases is expected to drive the sales in the global market.

What are the Factors Creating Restraints for the Growth in the Global Liver Fluke Treatment Market

There are numerous side effects related to the consumption of liver fluke treatment drugs such as praziquantel, albendazole, and nitazoxanide including itching, fever, dizziness, hair loss, vomiting, discolored urination, and others. Growing awareness regarding these side effects in hindering the sales in the market.

Also, stringent approval policies and regulations regarding the launch of novel liver fluke treatment solutions across various countries are further restraining the growth in the market.

Why is East Asia Garnering Maximum Sales of Liver Fluke Treatment in the Market

Future Market Insights reveals that East Asia is estimated to account for a lion’s share in the global liver fluke treatment market from 2022 to 2032.

With increasing emphasis on increasing the export of meat, wool, livestock, and others, the government of several countries are focusing on undertaking several initiatives to increase the breeding and population of cattle such as sheep.

For instance, as per the Food and Agriculture Organization, the population of sleep was reported to reach 16.58 Mn by 2019, exhibiting a year-on-year growth of around 1.2%. As sheep are highly prone to liver flukes, growing sheep population is projected to create lucrative opportunities in the East Asia market.

How is North America Contributing to the Growth in the Liver Fluke Treatment Market

As per a study by FMI, North America is anticipated to emerge as a highly remunerative market for liver fluke treatment during the forecast period 2022-2032.

A number of players in the market are focusing on developing and launching novel therapeutic drugs with minimal side effects and aiming at receiving product approval to cater to the surging demand for effective liver fluke treatment solutions in North America.

For instance, in 2019, Novartis, a global healthcare company, announced receiving Food & Drug Administration approval for its new liver fluke treatment drug, Egaten (triclabendazole), for patients six years of age and older in the U.S. A multiplicity of such developments is expected to drive the growth in the North America market.

Market Competition

Some of the leading players in the liver fluke treatment market are Novartis, GlaxoSmithKline Plc., Merck & Co., Inc., Pfizer Inc, Bayer HealthCare Pharmaceuticals Inc., Par Pharmaceutical, Romark Laboratories, L.C., Lupin Pharma, Schering Corporation among others.

Attributed to the presence of such high number of participants and increasing research and development activities for novel liver fluke treatment drug, the market is highly competitive.

Scope of Report

Report Attribute	Details
Growth Rate	CAGR of 4% to 5% from 2022 to 2032
Base Year for Estimation	2021
Historical Data	2015-2020
Forecast Period	2022-2032
Quantitative Units	Revenue in USD Billion, Volume in Kilotons and CAGR from 2022-2032
Report Coverage	Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis
Segments Covered	Drug Type Route of Administration Application Distribution Channel Region
Countries Covered	North America Latin America Europe East Asia South Asia Oceania Middle East and Africa
Key Companies Profiled	Novartis GlaxoSmithKline Plc. Merck & Co., Inc. Pfizer Inc Bayer HealthCare Pharmaceuticals Inc. Par Pharmaceutical Romark Laboratories, L.C. Lupin Pharma Schering Corporation Others
Customization	Available Upon Request

Key Segments Profiled in the Liver Fluke Treatment Market Survey

By Drug Type:

• Triclabendazole
• Praziquantel
• Bithionol
• Nitazoxanide
• Albendazole

By Route of Administration:

• Oral
• Intravenous
• Intramuscular
• Topical

By Application:

• Human
• Cattle
• Sheep
• Others

By Distribution Channel:

• Government Healthcare Centers
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacy

By Region:

• North America
• Latin America
• Europe
• East Asia
• South Asia
• Oceania
• Middle East and Africa